10:52:47 EDT Thu 05 Aug 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:IPSEY from 2020-08-06 to 2021-08-05 - 29 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-08-02 01:00U:IPSEYNews ReleaseIpsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
2021-07-29 01:00U:IPSEYNews ReleaseIpsen Delivers Strong H1 2021 Results and Upgrades Full-Year Guidance
2021-07-27 13:01U:IPSEYNews ReleaseIpsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway
2021-07-15 12:25U:IPSEYNews ReleaseIpsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson ’s Disease
2021-06-28 01:00U:IPSEYNews ReleaseExelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
2021-06-11 01:00U:IPSEYNews ReleaseISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity
2021-06-07 08:00U:IPSEYNews ReleaseExelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021
2021-06-01 13:00U:IPSEYNews ReleaseIpsen Announces the Launch of an Employee Shareholding Plan
2021-05-28 13:49U:IPSEYNews ReleaseIpsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP)
2021-05-11 17:00U:IPSEYNews ReleaseIpsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx ® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results
2021-04-22 01:00U:IPSEYNews ReleaseIpsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
2021-04-01 16:15U:IPSEYNews ReleaseFusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
2021-04-01 16:15U:IPSEYNews ReleaseFusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
2021-03-31 01:00U:IPSEYNews ReleaseEuropean Commission Approves Cabometyx ® in Combination With Opdivo ® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
2021-03-02 07:30U:IPSEYNews ReleaseFusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
2021-02-26 06:37U:IPSEYNews ReleaseIpsen Receives Positive CHMP Opinion Recommending Cabometyx ® in Combination With Opdivo ® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma
2021-02-22 01:00U:IPSEYNews ReleaseIpsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide)
2021-02-11 00:58U:IPSEYNews ReleaseIpsen Delivered Sales Growth and Margin Expansion in 2020 - Focused on Executing New Strategy and Delivering Financial Objectives in 2021
2021-02-05 01:00U:IPSEYNews ReleaseIpsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living With Renal Cell Carcinoma at ASCO GU 2021
2021-01-20 01:00U:IPSEYNews ReleaseIpsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
2020-12-01 01:00U:IPSEYNews ReleaseIpsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook
2020-11-30 16:58U:IPSEYNews ReleaseIpsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE ®) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)
2020-10-22 01:00U:IPSEYNews ReleaseIpsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 and Confirms Its 2020 Full Year Guidance
2020-09-25 01:00U:IPSEYNews ReleaseIpsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer
2020-09-19 12:30U:IPSEYNews ReleaseESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
2020-09-18 01:00U:IPSEYNews ReleaseESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months
2020-09-14 01:00U:IPSEYNews ReleaseIpsen Showcases Commitment to Patient-centric Advances in Oncology With Record Number of Abstracts to Be Presented at ESMO 2020 Virtual Congress
2020-09-10 01:00U:IPSEYNews ReleaseIpsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results
2020-08-25 01:00U:IPSEYNews ReleaseIpsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting